Nancy Reau to Hepacivirus
This is a "connection" page, showing publications Nancy Reau has written about Hepacivirus.
Connection Strength
4.639
-
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
Score: 0.701
-
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
Score: 0.698
-
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
Score: 0.495
-
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
Score: 0.354
-
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
Score: 0.349
-
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 Aug 24; 75(1):e955-e961.
Score: 0.198
-
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357.
Score: 0.187
-
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
Score: 0.187
-
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
Score: 0.163
-
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
Score: 0.163
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
Score: 0.158
-
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
Score: 0.143
-
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
Score: 0.130
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
Score: 0.130
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.124
-
Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
Score: 0.122
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
Score: 0.119
-
Willingness to participate in research among black patients with liver disease: A national cross-sectional study. J Viral Hepat. 2021 07; 28(7):982-993.
Score: 0.045
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
Score: 0.044
-
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
Score: 0.043
-
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
Score: 0.040
-
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32.
Score: 0.024
-
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012 Jun; 56(6):1276-82.
Score: 0.024